Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-silico discovery of common molecular signatures for which SARS-CoV-2 infections and lung diseases stimulate each other, and drug repurposing

18 Jul 2024

Abstract excerpt

COVID-19 caused by SARS-CoV-2 is a global health issue. It is yet a severe risk factor to the patients, who are also suffering from one or more chronic diseases including different lung diseases. In this study, we explored common molecular signatures for which SARS-CoV-2 infections and different lung diseases stimulate each other, and associated candidate drug molecules. We identified both SARS-CoV-2 infections...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Tuberculosis Research and Epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39024368
DOI: 10.1371/journal.pone.0304425

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-silico discovery of common molecular signatures for which SARS-CoV-2 infections and lung diseases stimulate each other, and drug repurposingPMID 39024368Read ↗

Meta-Data Analysis to Explore the Hub of the Hub-Genes That Influence SARS-CoV-2 Infections Highlighting Their Pathogenetic Processes and Drugs RepurposingSemantic proximity Read ↗

Depicting the innate immune response landscape in Covid-19 emphasized type 1 interferon a key defense against SARS-CoV-2Semantic proximity Read ↗

Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in severe acute respiratory syndrome corona virus 2 infection/COVID 19Semantic proximity Read ↗

Exploring Inflammatory Dysregulation in Alveolar Macrophages: Implications for Novel Therapeutic Targets in Chronic Obstructive Pulmonary DiseaseSemantic proximity Read ↗

Lung Disease Network Reveals the Impact of Comorbidity on SARS-CoV-2 Infection and Opportunities of Drug RepurposingSemantic proximity Read ↗

Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patientsSemantic proximity Read ↗

Integrated bioinformatics analysis to determine the impact of SARS-CoV-2 infections to Heart Failure patientsSemantic proximity Read ↗

Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approachesSemantic proximity Read ↗

Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approachesSemantic proximity Read ↗

Diseasome and comorbidities complexities of SARS-CoV-2 infection with common malignant diseasesSemantic proximity Read ↗

Transcriptome and SARS-CoV-2 biological network directed analysis for better therapeutic developmentSemantic proximity Read ↗

Transcriptomic Signatures and Repurposing Drugs for COVID-19 Patients: Findings of Bioinformatics AnalysesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.